Repligen Partners for Bipolar Disorder Clinical Trial Funds

Biopharmaceutical company Repligen Corp. and Stanley Medical Research Institute entered a development agreement that gives Repligen funding for a Phase I clinical trial for a treatment of bipolar disorder, the company announced. The clinical trial will assess the oral bioavailability of Repligen's proprietary formulation of uridine. The amount of the grant for the Waltham company was not disclosed.

Boston Business Journal (http://www.bizjournals.com/boston/stories/2005/03/14/daily7.html)